Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,791,081
  • Shares Outstanding, K 188,033
  • Annual Sales, $ 9,300 K
  • Annual Income, $ -643,200 K
  • EBIT $ -510 M
  • EBITDA $ -504 M
  • 60-Month Beta 1.09
  • Price/Sales 473.16
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 78.16% ( +4.53%)
  • Historical Volatility 47.76%
  • IV Percentile 76%
  • IV Rank 40.89%
  • IV High 132.96% on 06/18/24
  • IV Low 40.25% on 07/23/24
  • Put/Call Vol Ratio 0.08
  • Today's Volume 3,550
  • Volume Avg (30-Day) 2,874
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 135,604
  • Open Int (30-Day) 124,081

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -1.03
  • Number of Estimates 8
  • High Estimate -0.94
  • Low Estimate -1.13
  • Prior Year -1.08
  • Growth Rate Est. (year over year) +4.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.75 +12.00%
on 10/10/24
26.78 -4.85%
on 10/16/24
+0.68 (+2.74%)
since 10/01/24
3-Month
22.75 +12.00%
on 10/10/24
32.06 -20.52%
on 09/05/24
-0.70 (-2.67%)
since 08/01/24
52-Week
21.62 +17.85%
on 06/24/24
44.32 -42.51%
on 12/28/23
-1.17 (-4.39%)
since 11/01/23

Most Recent Stories

More News
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024

BBIO : 25.48 (+8.84%)
3 Top Stocks That Could Still Rocket Higher in 2024

Upcoming Food and Drug Administration decisions could push these stocks through the roof.

PTCT : 40.47 (+1.38%)
VRTX : 471.12 (-1.02%)
BBIO : 25.48 (+8.84%)
RHHBY : 39.2600 (+1.16%)
PFE : 28.09 (-0.74%)
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions

BBIO : 25.48 (+8.84%)
BridgeBio Pharma: Q2 Earnings Snapshot

BridgeBio Pharma: Q2 Earnings Snapshot

BBIO : 25.48 (+8.84%)
BridgeBio Pharma: Q1 Earnings Snapshot

BridgeBio Pharma: Q1 Earnings Snapshot

BBIO : 25.48 (+8.84%)
Stock Indexes Rally to Record Highs on a Resilient US Economy

The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +0.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.68%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.44%. Stocks on Thursday...

$SPX : 5,728.80 (+0.41%)
SPY : 571.04 (+0.42%)
$DOWI : 42,052.19 (+0.69%)
DIA : 420.42 (+0.66%)
$IUXX : 20,033.14 (+0.72%)
QQQ : 487.43 (+0.74%)
ZNZ24 : 110-010s (-0.40%)
MU : 99.73 (+0.08%)
WDC : 65.88 (+0.87%)
LRCX : 74.80 (+0.61%)
AMAT : 183.38 (+0.99%)
MRVL : 84.77 (+5.82%)
BridgeBio Pharma: Q4 Earnings Snapshot

BridgeBio Pharma: Q4 Earnings Snapshot

BBIO : 25.48 (+8.84%)
2 Biotechs That Could Get Bought Out in 2024

These two biotechs have been frequent visitors to the buyout-rumor mill and for good reason.

CYTK : 51.82 (+1.61%)
BBIO : 25.48 (+8.84%)
BridgeBio Pharma: Q3 Earnings Snapshot

BridgeBio Pharma: Q3 Earnings Snapshot

BBIO : 25.48 (+8.84%)
Why BridgeBio Pharma Was a Healthy Stock Today

One of the best-performing biotechs on the stock market this year gets a bullish nod from a researcher.

BBIO : 25.48 (+8.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United...

See More

Key Turning Points

3rd Resistance Point 28.59
2nd Resistance Point 27.11
1st Resistance Point 26.30
Last Price 25.48
1st Support Level 24.01
2nd Support Level 22.53
3rd Support Level 21.72

See More

52-Week High 44.32
Fibonacci 61.8% 35.65
Fibonacci 50% 32.97
Fibonacci 38.2% 30.29
Last Price 25.48
52-Week Low 21.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar